Tipsheet
What matters at India’s listed companies
Brief /Earnings / Healthcare

Fortis Healthcare profit climbs 31.5% to ₹1,064 crore in FY26

Consolidated revenue grew 17.3% as the hospital chain wrapped its fiscal year with an unmodified audit opinion.

6 earlier stories on Fortis Healthcare Ltd.
Mkt cap₹72,506 cr
P/E75.54×
ROE8.68%
Debt / eq.0.25
Div yld0.10%
₹1,064 cr Consolidated net profit for FY26, up 31.5% year-on-year.

What's new with Fortis Healthcare Ltd.

  • Revenue reached ₹9,128 crore, a 17.3% increase over the previous fiscal year.
  • Board declared a final dividend of ₹1 per equity share.
  • Statutory auditors B S R & Co. provided an unmodified opinion on the annual results.

Why this matters for Fortis Healthcare Ltd.

The double-digit growth in both top and bottom lines confirms steady demand for the company's network. An unmodified audit opinion provides the expected clean bill of health for these financial statements.

What we're watching

  • Management commentary on margin sustainability in the upcoming call.
  • The record date for the ₹1 dividend payout.
  • Capital allocation plans following this strong fiscal performance.

The full read

Fortis Healthcare closed FY26 with consolidated revenue of ₹9,128 crore, representing a 17.3% lift from the prior year. Profit growth outpaced the top line, climbing 31.5% to reach ₹1,064 crore.

Everything is clean.

Statutory auditors B S R & Co. signed off on the standalone and consolidated financials with an unmodified opinion. The board accompanied these numbers with a final dividend of ₹1 per share and appointed M/s Jitender, Navneet & Co. as cost auditor for the coming cycle. While the performance demonstrates clear momentum for this large-cap player, the market effectively priced these results in well before they arrived. Investors now look for guidance on how the firm plans to maintain these margins in a competitive healthcare landscape.

Mentioned: Fortis Healthcare · B S R & Co. · Jitender, Navneet & Co.
Primary source BSE · NSE · Tijori

Our reading of the company's own disclosure. Always confirm against the original source.